The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Early assessment of MCV to predict clinical outcome in patients with advanced gastrointestinal stromal tumors (GIST) receiving imatinib.
Anastasia Constantinidou
No relevant relationships to disclose
Dimitrios Krikelis
No relevant relationships to disclose
David Olmos
No relevant relationships to disclose
Michelle R. Scurr
No relevant relationships to disclose
Robin Lewis Jones
Honoraria - Novartis
Sue Ashley
No relevant relationships to disclose
Ian Robert Judson
Consultant or Advisory Role - Novartis (U)
Honoraria - Novartis
Research Funding - Novartis